» Articles » PMID: 24350576

Association of MicroRNA-126 Expression with Clinicopathological Features and the Risk of Biochemical Recurrence in Prostate Cancer Patients Undergoing Radical Prostatectomy

Overview
Journal Diagn Pathol
Publisher Biomed Central
Specialty Pathology
Date 2013 Dec 20
PMID 24350576
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Numerous studies have suggested that microRNA-126 (miR-126) is involved in development of various cancer types as well as in malignant proliferation and invasion. However, its role in human prostate cancer (PCa) is still unclear. The aim of this study was to investigate miR-126 expression in PCa and its prognostic value for PCa patients undergoing radical prostatectomy.

Methods: A series of 128 cases with PCa were evaluated for the expression levels of miR-126 by quantitative reverse-transcription PCR (qRT-PCR). Kaplan-Meier analysis and Cox proportional hazards regression models were used to investigate the correlation between miR-126 expression and prognosis of PCa patients.

Results: Compared with non-cancerous prostate tissues, the expression level of miR-126 was significantly decreased in PCa tissues (PCa vs. non-cancerous prostate: 1.05 ± 0.63 vs. 2.92 ± 0.98, P < 0.001). Additionally, the loss of miR-126 expression was dramatically associated with aggressive clinical pathological features, including advanced pathological stage (P = 0.001), positive lymph node metastasis (P = 0.006), high preoperative PSA (P = 0.003) and positive angiolymphatic invasion (P = 0.001). Moreover, Kaplan-Meier survival analysis showed that PCa patients with low miR-126 expression have shorter biochemical recurrence (BCR)-free survival than those with high miR-126 expression. Furthermore, multivariate analysis indicated that miR-126 expression was an independent prognostic factor for BCR-free survival after radical prostatectomy.

Conclusion: These findings suggest for the first time that the loss of miR-126 expression may play a positive role in the malignant progression of PCa. More importantly, the downregulation of miR-126 may serve as an independent predictor of BCR-free survival in patients with PCa.

Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1740080792113255.

Citing Articles

miRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer.

Salgado-Hernandez S, Martinez-Retamoza L, Ocadiz-Delgado R, Perez-Mora S, Cedeno-Arboleda G, Gomez-Garcia M Cancers (Basel). 2025; 17(1.

PMID: 39796656 PMC: 11718816. DOI: 10.3390/cancers17010026.


Monitoring of platelet function parameters and microRNA expression levels in patients with prostate cancer treated with volumetric modulated arc radiotherapy.

Bahtiyar N, Onaran I, Aydemir B, Baykara O, Toplan S, Agaoglu F Oncol Lett. 2018; 16(4):4745-4753.

PMID: 30250541 PMC: 6144890. DOI: 10.3892/ol.2018.9167.


Ultrasound‑targeted microbubble destruction‑mediated miR‑205 enhances cisplatin cytotoxicity in prostate cancer cells.

Qin D, Li H, Xie H Mol Med Rep. 2018; 18(3):3242-3250.

PMID: 30066866 PMC: 6102709. DOI: 10.3892/mmr.2018.9316.


The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.

Dankert J, Wiesehofer M, Czyrnik E, Singer B, von Ostau N, Wennemuth G PLoS One. 2018; 13(7):e0200472.

PMID: 30001402 PMC: 6042731. DOI: 10.1371/journal.pone.0200472.


MicroRNA-126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9.

Hua Y, Liang C, Miao C, Wang S, Su S, Shao P Oncol Lett. 2018; 15(6):9051-9060.

PMID: 29805636 PMC: 5958673. DOI: 10.3892/ol.2018.8528.


References
1.
Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y . Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep. 2013; 30(4):1976-84. DOI: 10.3892/or.2013.2633. View

2.
Saito Y, Friedman J, Chihara Y, Egger G, Chuang J, Liang G . Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun. 2009; 379(3):726-31. DOI: 10.1016/j.bbrc.2008.12.098. View

3.
Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg J . Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008; 456(7223):814-8. PMC: 3103772. DOI: 10.1038/nature07445. View

4.
Lovat F, Valeri N, Croce C . MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011; 38(6):724-33. DOI: 10.1053/j.seminoncol.2011.08.006. View

5.
Martin D, Starks A, Ambs S . Biological determinants of health disparities in prostate cancer. Curr Opin Oncol. 2013; 25(3):235-41. PMC: 6278601. DOI: 10.1097/CCO.0b013e32835eb5d1. View